Welcome to LookChem.com Sign In|Join Free

CAS

  • or

52574-06-8

Post Buying Request

52574-06-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

52574-06-8 Usage

Description

1-Methyl-5-oxo-L-Proline is a unique amino acid derivative that features a pyrrolidone carboxylic acid group in its structure, closely resembling the structure of proline, a proteinogenic amino acid integral to the construction of proteins within the body. Although it may not be as widely recognized or investigated as other amino acids, 1-Methyl-5-oxo-L-Proline holds promise for its potential applications in the fields of biomedical research and pharmaceuticals, with a particular focus on neurological conditions. Further research is essential to comprehensively understand its behavior and the full scope of its potential uses within biological systems.

Uses

Used in Biomedical Research:
1-Methyl-5-oxo-L-Proline is utilized as a research compound for investigating its interactions and effects within biological systems, particularly in the context of neurological conditions. Its structural similarity to proline may offer insights into the role of amino acids in neurological health and disease.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-Methyl-5-oxo-L-Proline is considered as a potential therapeutic agent, especially for conditions related to the nervous system. Its unique structure may contribute to the development of novel drugs that could target specific neurological pathways or mechanisms, thereby providing new treatment options for patients.
Used in Drug Delivery Systems:
1-Methyl-5-oxo-L-Proline may also be explored for its potential use in drug delivery systems, where its chemical properties could be leveraged to improve the efficacy and bioavailability of other pharmaceutical compounds, particularly those aimed at treating neurological disorders. The development of such systems could enhance the therapeutic outcomes for patients by ensuring more effective drug delivery to target areas within the body.

Check Digit Verification of cas no

The CAS Registry Mumber 52574-06-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,5,7 and 4 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 52574-06:
(7*5)+(6*2)+(5*5)+(4*7)+(3*4)+(2*0)+(1*6)=118
118 % 10 = 8
So 52574-06-8 is a valid CAS Registry Number.

52574-06-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid

1.2 Other means of identification

Product number -
Other names (S)-1-methyl-2-pyrrolidinone-5-carboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:52574-06-8 SDS

52574-06-8Relevant articles and documents

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

-

Paragraph 0560; 0562; 0563, (2021/04/17)

A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

-

Page/Page column 76, (2015/02/19)

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

-

Page/Page column, (2015/02/19)

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 52574-06-8